Vaxcyte (PCVX) net assets (shareholders' equity)

Net assets · fiscal 2025
$2.69B

Vaxcyte (PCVX) had net assets of $2.69B at the end of fiscal 2025 (December 31, 2025). That is 18.8% lower than the $3.31B of fiscal 2024. Figures as of 18 Nov 2026, 23:47 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$2.69B
Change on fiscal 2024
−18.8%
Growth, 5 years
+50.7% a year
Highest on record
$3.31Bfiscal 2024
Lowest on record
-$106.37Mfiscal 2019
Fiscal years on record
82018–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Vaxcyte net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets grew at a compound 50.7% a year. Across the 8 fiscal years on record (2018–2025), the highest was $3.31B in fiscal 2024 and the lowest -$106.37M in fiscal 2019.

History · 8 fiscal years

Net assets by fiscal year

Vaxcyte net assets (shareholders' equity), year by year

Vaxcyte (PCVX) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$2.69B 18.8% down
2024$3.31B 166.5% up
2023$1.24B 30.1% up
2022$953.61M 235.8% up
2021$284.02M 17.9% down
2020$345.84M—
2019-$106.37M—
2018-$57.73M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Vaxcyte and comparable companies
CompanyNet assetsFiscal year
Avantor AVTR$5.57B2025
Ensign Group ENSG$2.23B2025
Vaxcyte PCVX$2.69B2025
Bio-Rad Laboratories BIO$7.45B2025
Molina Healthcare MOH$4.07B2025
Spyre Therapeutics SYRE$715.24M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on PCVX

Vaxcyte, figure by figure

Vaxcyte (PCVX) overview: price, valuation and scorecardAll health care companies by market value

Vaxcyte net assets (shareholders' equity): questions and answers

What are Vaxcyte's net assets?

Vaxcyte (PCVX) had net assets of $2.69B at the end of fiscal 2025 (December 31, 2025). That is 18.8% lower than the $3.31B of fiscal 2024.

What is the growth rate of Vaxcyte's net assets?

Over the five fiscal years to 2025 net assets grew at a compound 50.7% a year.

What are the highest and lowest net assets figures on record for Vaxcyte?

Across the 8 fiscal years on record (2018–2025), the highest was $3.31B in fiscal 2024 and the lowest -$106.37M in fiscal 2019.

How is Vaxcyte's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Vaxcyte it is on record here for 8 fiscal years, 2018 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Vaxcyte (PCVX) net assets (shareholders' equity)”, data as of 18 November 2026. https://funkfolio.com/stock/PCVX/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.